Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04054414 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

PMZ-1620 (Sovateltide) in Patients of Acute Spinal Cord Injury

StatusRecruiting
PhasePhase 2
Started2019-01-10
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 4, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
This was a prospective, multicentric, randomized, double blind, parallel, saline controlled Phase II clinical study to compare the safety and efficacy of PMZ-1620 (INN: Sovateltide) therapy along with standard supportive care in patients of acute spinal cord injury.

Amendment record

Amended 5 times since 2019-08-11; most recent filed 2025-07-01. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-30.

2025-07-01
Amendment Study Status, Oversight v5
2023-07-07
Amendment Study Status v4
2022-08-22
Amendment Study Status v3
2021-09-29
Amendment Study Status v2
2020-09-14
Amendment Study Status v1
2019-08-11
Original filing
Trial Details
NCT Number NCT04054414
Lead Sponsor Pharmazz, Inc.
Conditions Acute Spinal Cord Injury
Enrollment 40 participants
Start Date 2019-01-10
Primary Completion 2026-06 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2025-07-04